Notice of Clarification to RFA-DA-15-004 "NIDA Avant-Garde Award Program for HIV/AIDS and Drug Use Research (DP1)"

Notice Number: NOT-DA-14-015

Key Dates
Release Date: July 2, 2014

Related Announcements

Issued by
National Institute on Drug Abuse (NIDA)


This Notice is to correct the Letters of Reference section in RFA-DA-15-004 "NIDA Avant-Garde Award Program for HIV/AIDS and Drug Use Research (DP1)".

Instead of referencing "RFA-DA-15-005" the FOA should now read:

Part 2. Section IV.6. Other Submission Requirements and Information

Letters of Reference

Letters of reference are an important aspect of the application. Applicants must arrange to have three (and no more than three) letters of reference submitted on their behalf. Applications that are missing letters of reference will be considered incomplete and will not be reviewed. Late letters will not be accepted. Applicants are responsible for monitoring the submission of their letters to ensure that three letters have been submitted prior to the submission deadline. Applicants are encouraged to check the status of their letters in their Commons accounts.

Letters may be submitted beginning June 29 and must be submitted no later than 5:00 p.m. (local time of applicant organization), July 29.

To submit a letter of reference, the referee will need the following information:

  • Funding Opportunity Number (FOA) for this announcement: RFA-DA-15-004
  • The applicant's eRA Commons User Name (Note: Referees do not need to be registered in the Commons and do not need their own Commons User Name – only the Commons User Name of the applicant is required);
  • The applicant's first and last name (note – the name must match exactly the applicant's name in the Commons);

All other aspects of the FOA remain the same.


Please direct all inquiries to:

Jacques Normand, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-443-1470